Isabelle Loubinoux
  • E-mail :[email]
  • Phone : +33 5 62 74 61 83
  • Location : Toulouse, France
Last update 2012-09-11 15:32:23.8

Isabelle Loubinoux PhD Medical Imaging

Course and current status

Current position: Researcher at INSERM U825

Laboratory: Cerebral Imagery and neurologic Handicap (Head : Pierre Celsis)

Isabelle LOUBINOUX: PhD, Senior researcher (Directeur de Recherches)

Head of team 3: Therapeutic innovations in cerebrovascular disease

h-index: 18

Education and qualifications:

2011            Senior researcher

2006-2011   Contrat d’interface: Innovative strategies in Stroke

2010            Aptitude to experimental neurosurgery. Neuroanatomy, neurohistology and neurosurgery of laboratory animals (Veterinary school of Toulouse).

2010            Head of team 3 at Inserm U825.

2006            Collaboration in L.G. Cohen’s laboratory at the NIH/NINDS (Bethesda, 5 months).

                  - Learning in healthy subjects and stroke patients (MRI, rTMS).

2006            Aptitude to conduct experimental research in animals (Veterinary school of Toulouse).

2003            Degree from the CESAM Paris VI (Centre d’Enseignement de la Statistique Appliquée à la Médecine et à la biologie médicale). Design of Clinical trials.

2002            Aptitude to conduct Research in Neurosciences (UPS Toulouse).

2000            Position as researcher at INSERM.

1996-2000    Post-graduate: Post-doctoral training at INSERM U455

1995            Graduate: Ph.D, University of Paris XI, Speciality: MEDICAL IMAGING. Très honorable avec les félicitations du jury. CNRS (URA 641, Paris).

Scientific summary

Within the unit 825, Isabelle Loubinoux'team has been dealing with with stroke disease since 16 years. Her team (3) was created by Inserm CSS3 in 2011.
We have a close collaboration with the neurological department (F. Chollet, J-F Albucher, N Raposo, J. Pariente, B Acket), the rehabilitation department (Pr Roques, P. Marque, X de Boissezon, E Castel-Lacanal) and the Center of Clinical Investigation (O. Rascol, C. Thalamas).
   We have access to heavy equipment: a 3T MRI entirely devoted to research, research sessions made available at the PET Centre of the university hospital, primate animal housing and a small-animal house equipped with suitable imaging tools (7T MRI and micro-PET). The technical facilities also include stereotactic transcranial magnetic stimulation.

The main objectives of the ongoing project are on the one hand to develop and adapt advanced neuroimaging techniques to translational and clinical research, and, on the other hand, to couple these neuroimaging techniques to brain stimulation techniques in patients and controls for a better understanding of the pathophysiological mechanisms of the neurological disorders or handicaps, so as to improve their early diagnosis and to define adapted therapeutic or rehabilitative approaches.
   Our project needs to determine experimentally the therapeutical strategies that will have a major clinical impact on future clinical treatments for stroke specifically in highly invalidated patients. Hemiplegia is the more common deficit. First cause of handicap, stroke has a heavy economical cost. Our main result is that ipsilesional activity must be promoted. Non invasive stimulation focused on this cerebral cortex show a certain efficacy on motor recovery. Its modalities must be determined before being applied to the clinic. Virtual reality could help recovery of patients at home. Today, no pharmacological treatment has been validated in human clinical when deficits are constituted.
   We demonstrated that Prozac significantly augments the ratio of independent patients. Other hopes rely on cerebral bioprosthesis (cellular therapy combined with biomaterials).

Image d’exemple